November 22, 2005 -- The market for opioid painkillers is big, and new players are entering, hoping to wrest sales from OxyContin, a Purdue Pharma product, by separating the therapeutic value of the drug from its potential for abuse. Recently, Pain Therapeutics watched its stock price rise 50% after it signed a $300 million deal with King Pharma. But today it gave back most of the gain when one of its products failed to meet a Phase III endpoint. We look at the abuse-resistant opioid field and its investment potential...
